Natera, Inc. Share Price

Equities

NTRA

US6323071042

Healthcare Facilities & Services

Market Closed - Nasdaq 21:00:00 14/06/2024 BST 5-day change 1st Jan Change
110.2 USD -0.53% Intraday chart for Natera, Inc. -0.89% +75.93%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 1.43B 113B Sales 2025 * 1.68B 132B Capitalization 13.53B 1,067B
Net income 2024 * -298M -23.5B Net income 2025 * -139M -10.96B EV / Sales 2024 * 9.11 x
Net cash position 2024 * 472M 37.22B Net cash position 2025 * 520M 40.99B EV / Sales 2025 * 7.75 x
P/E ratio 2024 *
-44.7 x
P/E ratio 2025 *
-94.5 x
Employees 3,288
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.8%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.53%
1 week-0.89%
Current month+3.45%
1 month+4.44%
3 months+25.64%
6 months+82.84%
Current year+75.93%
More quotes
1 week
108.62
Extreme 108.62
117.23
1 month
104.79
Extreme 104.785
117.23
Current year
58.53
Extreme 58.53
117.23
1 year
36.90
Extreme 36.9
117.23
3 years
26.10
Extreme 26.1
129.09
5 years
16.87
Extreme 16.87
129.09
10 years
6.52
Extreme 6.52
129.09
More quotes
Managers TitleAgeSince
Chief Executive Officer 45 30/11/10
Founder 51 31/10/03
Founder 51 31/10/03
Members of the board TitleAgeSince
Director/Board Member 59 31/10/14
Director/Board Member 50 31/12/06
Director/Board Member 76 31/01/14
More insiders
Date Price Change Volume
14/06/24 110.2 -0.53% 806,190
13/06/24 110.8 -1.61% 646,416
12/06/24 112.6 +0.12% 1,041,253
11/06/24 112.5 +0.73% 824,716
10/06/24 111.7 +0.42% 1,370,538

Delayed Quote Nasdaq, June 14, 2024 at 09:00 pm

More quotes
Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
110.2 USD
Average target price
123.5 USD
Spread / Average Target
+12.07%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW